ArticleJournal of the National Cancer Institute2026
Subsequent breast cancer risk after benign breast biopsy in racially diverse women: Siteman Cancer Center.
Article in Journal of the National Cancer Institute, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Breast Cancer Risk After Benign Breast Disease Among Racially Diverse Women: Systematic Review and Meta-Analysis.Research square · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundThe association between histological subtypes of benign breast disease and subsequent breast cancer risk in the postmammography era of increased benign breast disease detection requires continued study to inform the clinical management of high-risk women.
methodsWe identified a cohort of 8915 women diagnosed with histologically confirmed benign breast lesions between 2010 and 2023 from the Joanne Knight Breast Health Center in St. Louis. Risk of subsequent breast events after a benign breast biopsy was assessed with Cox regression to estimate hazard ratios (HRs) and 95% confidence intervals (95% CIs).
resultsWithin a median follow-up of 6.5 years, 363 women developed breast cancer. The cohort was 63.7% White, 32.4% Black, and 3.9% Asian race. Breast cancer risk increased across subtypes of benign breast disease, from proliferative disease without atypia to atypical hyperplasia, with atypical hyperplasia risk modified by time since biopsy and menopause. Compared with women with nonproliferative disease, age-adjusted risk for breast cancer was 1.69 for proliferative disease without atypia (HR = 1.69, 95% CI = 1.35 to 2.12) and 2.78 for atypical hyperplasia (HR = 2.78, 95% CI = 2.01 to 3.85; P < .0001 for trend). Risk estimates attenuated but remained similar in fully adjusted models. Risks associated with benign breast disease subtypes were similar for Black and White women, but Black women with atypical hyperplasia had greater risk of breast cancer since recent biopsy (≤4 years) and during the premenopausal period (P = .033 for heterogeneity).
conclusionBreast cancer risk increases with the degree of epithelial proliferation, highest in atypical hyperplasia, amplified by recent biopsy and premenopause, particularly in Black women, consistent with the excess risk seen after ductal carcinoma in situ in this group.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.